Updated Austrian treatment algorithm in HER2+ metastatic breast cancer

Summary A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scen...

Full description

Saved in:
Bibliographic Details
Published in:Wiener Klinische Wochenschrift 2022, Vol.134 (1-2), p.63-72
Main Authors: Bartsch, Rupert, Gampenrieder, Simon Peter, Rinnerthaler, Gabriel, Petru, Edgar, Egle, Daniel, Petzer, Andreas, Balic, Marija, Pluschnig, Ursula, Sliwa, Thamer, Singer, Christian
Format: Article
Language:English
Subjects:
Algorithms
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Austria
Breast Neoplasms - drug therapy
Consensus Report
Endocrinology
Female
Gastroenterology
Humans
Internal Medicine
Medicine
Medicine & Public Health
Pneumology/Respiratory System
Receptor, ErbB-2 - genetics
Receptor, ErbB-2 - therapeutic use
Trastuzumab - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.
ISSN:0043-5325
1613-7671
DOI:10.1007/s00508-021-01987-9